Skip to content

Homepage

Author: NurExone Biologic Inc

Posted Date:

June 30, 2026

NurExone Announces Closing of Non-Brokered Private Placement

NurExone Biologic Inc

June 30, 2026
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

NurExone Biologic Inc

June 24, 2026
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

NurExone Biologic Inc

June 1, 2026
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

NurExone Biologic Inc

May 28, 2026
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

NurExone Biologic Inc

May 27, 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

NurExone Biologic Inc

May 25, 2026
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

NurExone Biologic Inc

May 24, 2026
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

NurExone Biologic Inc

May 22, 2026
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

NurExone Biologic Inc

May 22, 2026
NurExone Announces Corporate Updates

NurExone Biologic Inc

April 30, 2026

1 2